TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A large survey-based study found nail disorders, including nail separation, were more common among GLP-1 receptor agonist users than among people with obesity or diabetes who had never taken the drugs. The association weakened after accounting for other factors, and an analysis of new-onset cases found no difference, so the findings do not establish that GLP-1 drugs cause nail changes.
A study of 575 GLP-1 receptor agonist users found that nail separation and discoloration were reported more often than among a comparison group with obesity and/or type 2 diabetes who had never used the drugs. The findings, presented at a European Academy of Dermatology and Venereology meeting, show an association—not proof that the medicines caused the nail changes—and an analysis of newly appearing cases found no difference between users and non-users.
In the study, 39.3% of GLP-1 users reported onycholysis, or separation of the nail from its nail bed, compared with 8.7% of the 1,329 non-users. The report described this as a 4.5-fold higher likelihood among users. Nail discoloration, called dyschromia, was reported by 45.6% of users and 17.0% of non-users, a 2.7-fold difference. Fragile nails and ridges or grooves were also more common in the GLP-1 group.
Overall, 66.3% of users and 52.8% of non-users reported at least one nail disorder, a statistically significant difference (P<0.001). The study included participants recruited in France, the United States, Brazil and Mexico. The control group was older on average—56.7 years compared with 45.3 among users—while the groups had a roughly even sex distribution.
Researchers reported that adjusting for factors such as age, sex, country and comorbidities reduced but did not eliminate some associations. However, nearly half of GLP-1 users said they had a history of nail problems before treatment. When the analysis focused on new-onset nail lesions, it found no difference in onycholysis or discoloration between users and non-users. The data were collected through an online survey, rather than examinations of participants’ nails by dermatologists.
What the Nail Findings Could Mean
The results flag nail changes as a possible issue for clinicians to ask about when patients use GLP-1 medicines, which are prescribed for conditions including type 2 diabetes and obesity. If a patient notices nail separation, discoloration or other changes, the timing—whether it began before or after treatment—may help a clinician assess potential causes. The study does not establish that the drugs are responsible, and its conflicting analyses make that distinction especially important.
Outside expert Joe Tung of the University of Pittsburgh Medical Center, who was not involved in the research, said the findings should not prompt people doing well on a GLP-1 medication to stop taking it. He told MedPage Today that common nail disorders have treatable causes and recommended medical assessment for people who notice changes. The study itself does not provide evidence to change treatment decisions.
nail health supplements for brittle nails
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Researchers Tested the Association
The work was presented by Bianca Maria Piraccini, of the University of Bologna in Italy, at the European Academy of Dermatology and Venereology meeting in Vienna. Co-investigator Charles Taieb, of European Market Maintenance Assessment in France, described it as one of the first large-scale analyses of nail and hair effects associated with GLP-1 receptor agonists. Earlier reports of nail changes during GLP-1 treatment had been largely anecdotal, according to Taieb.
Piraccini said investigators compared users with a group of people with obesity and/or diabetes who had never taken a GLP-1 drug. She reported that analyses accounting for comorbidities, including dermatologic conditions, continued to show higher odds of onycholysis and dyschromia among users. An analysis restricted to participants who had lost weight did not appreciably change the results. However, the report also notes that pre-existing nail problems were common among users and that the new-onset analysis did not show a difference.
Piraccini said weight loss can be associated with surface changes to nails, but argued that nail detachment is not typically a sign of low calorie intake or protein deficiency. She said the researchers considered other potential causes, including trauma and fungal infection. Those interpretations are the investigators’ assessment; the survey design and findings do not establish a direct drug effect.
““These findings alone, however, would not justify stopping an otherwise beneficial GLP-1 medication for the appropriate patient.””
— Joe Tung, University of Pittsburgh Medical Center, who was not involved in the study
As an affiliate, we earn on qualifying purchases.
Cause and Timing Remain Unsettled
The central uncertainty is whether GLP-1 medicines contribute directly to nail disorders. The higher overall rates and adjusted associations suggest a possible link, but the new-onset analysis found no difference. Nearly half of users reported nail problems before starting treatment, complicating efforts to connect the conditions to the medicines. The source report says sensitivity analyses accounting for prior nail problems still found differences in some comparisons, while the new-onset analysis did not.
The study relied on an online survey and self-reported nail changes, with no dermatologist examining participants, according to Tung. The available report does not provide enough detail to resolve how much the results may reflect differences between the groups, recall or reporting, or other health and nutritional factors. The researchers’ suggestion that the association may fall between adjusted and new-onset results is an interpretation, not a settled finding. The source also does not specify the GLP-1 drugs, doses or treatment durations for each participant.
nail discoloration treatment products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Further Research and Clinical Follow-Up
Piraccini said the findings will prompt the team to conduct more studies. Further research would need to clarify whether nail changes begin after treatment, how frequently they occur, and whether any relationship remains when nail disorders are assessed directly and other causes are accounted for. The meeting report did not provide a timeline for additional studies.
For now, Piraccini advised clinicians to ask whether nail problems were present before GLP-1 treatment and to examine affected nails. Tung said patients noticing changes should seek assessment from a dermatologist, while cautioning that these findings alone are not a reason to stop an otherwise beneficial medication. Decisions about treatment should be made with the prescribing clinician.
As an affiliate, we earn on qualifying purchases.
Key Questions
What nail changes were reported more often among GLP-1 users?
The study reported higher rates of onycholysis, or nail separation, and dyschromia, or discoloration. Nail fragility and ridges or grooves were also reported more often among users.
Does the study show that GLP-1 drugs cause detached nails?
No. It found an association in survey data, but does not establish causation. An analysis limited to nail lesions that began after treatment found no difference between users and non-users.
Should someone stop taking a GLP-1 medicine because of nail changes?
The outside expert quoted in the report said the findings alone do not justify stopping an otherwise beneficial GLP-1 medicine. Anyone concerned about nail changes should discuss them with a qualified clinician before making treatment decisions.
How common were nail problems in the study?
At least one nail disorder was reported by 66.3% of GLP-1 users and 52.8% of non-users. These were survey findings from the study groups, not estimates of risk for every person taking a GLP-1 medicine.
What should researchers investigate next?
Further work needs to determine whether nail changes start after treatment and whether a drug-related association remains when researchers assess nails directly and account for other potential causes. The study presenter said the findings would prompt additional studies, but no schedule was given.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
